News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2025

10 December, 2025 Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe News Corporate Information Other Corporate Information English IR Optional
4 December, 2025 New publication highlights meaningful clinical benefits of Emcitate® (tiratricol) in treating Resistance to Thyroid Hormone Beta News Corporate Information Other Corporate Information English IR Optional
1 December, 2025 Members of Egetis' Leadership Team acquire shares in Egetis News Corporate Information Other Corporate Information English IR Optional
27 November, 2025 Chairman of the Board of Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English IR Optional
25 November, 2025 Interim report Q3 2025 News English Regulatory MAR Report Interim Q3 IR Optional
21 November, 2025 Invitation to Presentation of Egetis’ Third Quarter 2025 Report on November 25, 2025 News Corporate Information Presentation English IR Optional
14 November, 2025 Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratricol) in MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
6 November, 2025 Egetis Therapeutics to Participate in Upcoming November Investor Conferences News Corporate Information Other Corporate Information English IR Optional
31 October, 2025 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
23 October, 2025 Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
15 October, 2025 Egetis and taiba rare Sign Exclusive Distribution and Early Access Agreement to Enable Named Patient Sales of Emcitate® in the Gulf Region News Corporate Information Other Corporate Information English IR Optional
10 October, 2025 Egetis’ Nomination Committee for the 2026 Annual General Meeting News Corporate Information Nomination Committee English IR Optional
2 October, 2025 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
2 October, 2025 Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer
21 August, 2025 Interim report Q2 2025 News English Regulatory MAR VPML Report Interim Q2 IR Optional
19 August, 2025 Invitation to Presentation of Egetis’ Second Quarter 2025 Report on August 21, 2025 News Corporate Information Other Corporate Information English IR Optional
18 August, 2025 Egetis reports progress towards US NDA submission for tiratricol News Corporate Information Other Corporate Information English IR Optional
17 July, 2025 CFO of Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English IR Optional
15 July, 2025 Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
16 June, 2025 Egetis announces exclusive distribution agreement with Er-Kim for Emcitate® in Türkiye News Corporate Information Other Corporate Information English IR Optional
10 June, 2025 CEO and members of Egetis' Leadership Team acquire shares in Egetis News Corporate Information Other Corporate Information English IR Optional
6 May, 2025 Bulletin from Egetis Therapeutics’ Annual General Meeting 2025 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
5 May, 2025 Egetis Confirms Launch of Emcitate® in Germany News Corporate Information Other Corporate Information English IR Optional
30 April, 2025 Interim report Q1 2025 News English Regulatory MAR Report Interim Q1 IR Optional
25 April, 2025 Invitation to Presentation of Egetis’ First Quarter 2025 Report on April 30, 2025 News Corporate Information Other Corporate Information English IR Optional
Next

Calendar and upcoming reports

January 12-13, 2026
JP Morgan Healthcare Week (San Francisco, CA)

February 26, 2026 (7:00am CET)
Year-end Report Q4 2025

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]